tirzepatide · new-zealand

Tirzepatide in New Zealand

Mounjaro launched in New Zealand February 2026 via Eli Lilly. Medsafe-approved, not Pharmac-subsidised for weight. Private prescription via telehealth is the primary legal route; expect around NZD 429 per month on a typical protocol.

Legal status

Medsafe-approved (brand Mounjaro), February 2026 launch via Eli Lilly. Prescription-only. Pharmac not subsidising for weight management; diabetes subsidy under review.

Monthly price bands

What it actually costs.

Midpoint ranges, Eli Lilly brand unless noted. Updated April 2026.

Private prescription (off-label weight)

NZD, per month on 5 to 10 mg. Telehealth dominates.

$260 to $430
/ month
Private prescription (on-label T2D)

NZD. Some private insurers partially reimburse with diabetes dx.

$220 to $350
/ month
Legal routes

How to get it — on the right side of the line.

Route 1

New Zealand telehealth clinics

A handful of NZ-based telehealth operators started Mounjaro prescribing in Q1 2026. Video consult + local pharmacy dispense is the standard flow.

Route 2

Australia cross-border script

Australian private Rx from Juniper or Eucalyptus can sometimes be filled at a New Zealand pharmacy. Check with the pharmacy before relying on this.

Availability by channel

What channels actually work here.

Clinic (brand)
Available

Post-Feb 2026 launch.

Compounding pharmacy
Not routed

Not common in NZ.

Research-chem direct
Not routed

Customs blocks.

Telehealth
Available

Nascent but growing.

In practice

NZ content is thin; most Kiwi patients still find Australian or US-focused content in search. Panya's regional content fills that gap directly. For cost-sensitive NZ patients, a short trip to Thailand breaks even around 4 months of continuous use.

Ready

Match me to a vendor in New-zealand.

Two minutes, five questions. Your match email has the vendor name, price, and the honest tradeoff.

We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.